| Zacks Company Profile for Pacira BioSciences, Inc. (PCRX : NSDQ) |
|
|
| |
| • Company Description |
| Pacira BioSciences Inc. delivers non-opioid pain therapies to transform the lives of patients. The company's commercial stage non-opioid treatments EXPAREL(R) a long-acting local analgesic for post-surgical pain management and ZILRETTA(R) an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. Pacira BioSciences Inc., formerly known as PACIRA PHARMACT, is based in PITTSBURGH, Calif.
Number of Employees: 829 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $36.42 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,643,391 shares |
| Shares Outstanding: 39.86 (millions) |
| Market Capitalization: $1,451.77 (millions) |
| Beta: 0.25 |
| 52 Week High: $36.67 |
| 52 Week Low: $18.80 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
42.49% |
43.99% |
| 12 Week |
35.04% |
31.74% |
| Year To Date |
40.73% |
25.43% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
2000 SIERRA POINT PARKWAY SUITE 900
-
BRISBANE,CA 94005
USA |
ph: 650-242-8052
fax: 302-655-5049 |
susan.mesco@pacira.com |
http://www.pacira.com |
|
|
| |
| • General Corporate Information |
Officers
Frank D. Lee - Chief Executive Officer and Director
Laura Brege - Chairman
Lauren Riker - Senior Vice President; Finance
Shawn M. Cross - Chief Financial Officer
Marcelo Bigal - Director
|
|
Peer Information
Pacira BioSciences, Inc. (GSAC)
Pacira BioSciences, Inc. (CASIF)
Pacira BioSciences, Inc. (ALCD.)
Pacira BioSciences, Inc. (OMNN)
Pacira BioSciences, Inc. (CGPI.)
Pacira BioSciences, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 695127100
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/05/26
|
|
Share - Related Items
Shares Outstanding: 39.86
Most Recent Split Date: (:1)
Beta: 0.25
Market Capitalization: $1,451.77 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.57 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $1.86 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/05/26 |
|
|
|
| |
